Shots:

• The positive CHMP opinion of Forxiga (dapagliflozin) follows P-III DECLARE-TIMI 58 study evaluating the CV outcomes in 17-000+ patients with T2D across 33 countries resulted in reduction in hospitalization for HF or CV death
• The positive CHMP opinion of Fasenra (prefilled syringe and auto-injector pen) follows P-III GREGALE and GRECO & P-I AMES study evaluating the prefilled syringe & auto-injector device in patients with severe- uncontrolled asthma
• Forxiga is a SGLT2 inhibitor- indicated as both monothx. & combination therapy for impoving glycaemic control as an adjunct to diet and exercise in adults with T2D and is under regulatory review in the US- China & Japan. Fasenra (benralizumab) is a mAb targeting IL-5 receptor alpha on eosinophils with its anticipated FDA’s approval in H2’19

Click here- Click here to read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca